Skip to content
value.today

Grifols, S.A.: financial analysis

Ratios worked out from 7 fiscal years of Grifols, S.A.'s statements, compared with 102 companies in Pharmaceutical.

Operating margin, 2025
16.5%
Pharmaceutical: 1.8%
Return on equity, 2025
5.1%
Pharmaceutical: -0.9%
Free cash flow margin, 2025
10.4%
Pharmaceutical: 6.0%

Grifols, S.A. scorecard#

Passes 4 of the 6 checks that could be worked out. Fiscal year 2025; market cap of Aug 1, 2026.

  • Valuationnot known
    • –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
    • –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
    • –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
  • Growth1 of 2
    • ✓Revenue grew in the newest year8.7%Revenue up 8.7% in fiscal 2025.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • ✗Net income higher than five years earlier$453 M$453 M in fiscal 2025 against $705 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability2 of 3
    • ✓Profitable in the newest year$453 MNet income $453 M in fiscal 2025.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • ✓Operating margin above its peers' median16.5%16.5% against Pharmaceutical's median of 1.8% (74 companies).
    • ✗Return on equity above 15%5.1%5.1% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 1
    • –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (esef, wikidata), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Piotroski F-score

Nine yes/no tests of whether the company's finances improved in the year. One point each.

5of 6(3 of the nine tests cannot be worked out from the statements on file, so there is no full score)
  • Made a profityes
  • Operations brought in cashyes
  • Return on assets roseyes
  • Cash from operations exceeds profityes
  • Long-term debt fell against assetsnot on file
  • Current ratio rosenot on file
  • No new shares issuednot on file
  • Gross margin roseno
  • Asset turnover roseyes

Where the return on equity comes from

The DuPont split: margin, times how hard the assets work, times how much of them is financed by others.

Net margin5.3%Asset turnover0.37×Assets to equity2.57×Return on equity5.1%

Profitability#

Grifols, S.A.: profitability by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Gross margin38.0%38.7%37.7%——53.3%28%
Operating margin16.5%16.5%11.9%——1.8%79%
Net margin5.3%2.2%0.6%——-1.5%63%
Return on equity5.1%2.0%0.5%——-0.9%59%
Return on assets2.0%0.8%———-1.3%60%

Growth#

Grifols, S.A.: growth by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Revenue growth8.7%9.5%———7.3%60%
Net income growth166.8%274.2%———14.3%97%

Financial strength#

Grifols, S.A.: financial strength by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Equity share of assets38.6%40.2%———47.3%40%

Cash#

Grifols, S.A.: cash by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Free cash flow$882 M$724 M$-8 M——$8 M81%
Free cash flow margin10.4%9.3%-0.1%——6.0%66%
Cash conversion260.5%574.5%516.7%——136.7%72%
Capital spending share of revenue3.5%3.2%3.4%——2.6%—

Efficiency#

Grifols, S.A.: efficiency by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Asset turnover0.37×0.35×———0.55×21%

How each figure is worked out#

Gross margin
Gross profit as a share of revenue.
Operating margin
Operating income as a share of revenue.
Net margin
Net income as a share of revenue.
Return on equity
Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
Return on assets
Net income as a share of total assets (average of the year).
Revenue growth
Revenue against the year before.
Net income growth
Net income against the year before. Only when both years were profitable.
Equity share of assets
Shareholders' equity as a share of total assets.
Free cash flow
Cash from operations less capital spending.
Free cash flow margin
Free cash flow as a share of revenue.
Cash conversion
Cash from operations as a share of net income. Only when the year was profitable.
Capital spending share of revenue
Capital spending as a share of revenue.
Asset turnover
Revenue divided by total assets (average of the year).

Source: Grifols, S.A.'s statements: annual reports in the European single electronic format; Wikidata. Arithmetic on reported figures, in US dollars; nothing is estimated. A figure is blank when a line it needs is not in the statements on file, and left out when the result cannot be right (a margin from next to no revenue). "Ahead of" is the share of the 102 companies in Pharmaceutical that Grifols, S.A. is better than on that figure, using each company's newest fiscal year; yields use today's market value. Medians for every industry · Back to Grifols, S.A.